A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers.

A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor
Female
Humans
Indazoles
Kaplan-Meier Estimate
Male
Middle Aged
Mutation
Protein Kinase Inhibitors
Pyridones
Pyrimidines
Pyrimidinones
Receptors, Vascular Endothelial Growth Factor
Sulfonamides
Thyroid Neoplasms
Treatment Outcome

authors with profiles

STEVEN I SHERMAN
VIVEK SUBBIAH